The 6 analysts offering 12-month price forecasts for CureVac NV have a median target of 14.88, with a high estimate of 20.86 and a low estimate of 7.87. The median estimate represents a +184.00% increase from the last price of 5.24.
The current consensus among 8 polled investment analysts is to Buy stock in CureVac NV. This rating has held steady since December, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.25
Reporting Date Apr 24
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.